United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biogen idec ltd - peginterferon beta-1a - solution for injection - 188microgram/1ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أداتكو - adatco drug store - interferon beta-1a 30 mcg/0.5ml - 30 mcg/0.5ml

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen idec australia pty ltd - interferon beta-1a -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck serono australia pty ltd - interferon beta-1a -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b -

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - interferon beta-1b - injection, powder, for solution - 0.25 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer ag, germany - interferon beta-1b - powder and solvent for solution for injection - 8000000 iu/ml

Canada - English - Health Canada

novartis pharmaceuticals canada inc - interferon beta-1b - powder for solution - 0.3mg - interferon beta-1b 0.3mg - immunomodulatory agents

United States - English - NLM (National Library of Medicine)

genentech, inc. - peginterferon alfa-2a (unii: q46947fe7k) (peginterferon alfa-2a - unii:q46947fe7k) - peginterferon alfa-2a 180 ug in 1 ml - adult patients: pegasys, as part of a combination regimen with other hepatitis c virus (hcv) antiviral drugs, is indicated for the treatment of adults with chc and compensated liver disease. for information about the safe and effective use of other hcv antiviral drugs to be used in combination with pegasys, refer to their prescribing information. pegasys monotherapy is only indicated for the treatment of patients with chc and compensated liver disease if there are contraindications or significant intolerance to other hcv antiviral drugs. pediatric patients: pegasys in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with chc and compensated liver disease. limitations of use : - pegasys alone or in combination with ribavirin without additional hcv antiviral drugs is not recommended for treatment of patients with chc who previously failed therapy with an interferon-alfa. - pegasys is not recommended for treatment of patients with chc who have had solid